A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical NanoxelM (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer
Phase of Trial: Phase III
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Mitomycin
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Samyang Biopharmaceuticals Corporation
- 28 Aug 2019 Status changed from recruiting to discontinued.
- 16 Apr 2018 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.
- 01 Feb 2017 New trial record